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Abstract 
Purpose: The main aim of this study was to investigate the effects of Portulaca 
oleracea extract on tumor formation in colon cancer stem cells and chemotherapy 
sensitivity. In addition, this study analyzed the genetic changes within the Notch 
signal transduction pathway associated with the effects of the extracts.   
Methods: Serum-free cultures of colon cancer cells (HT-29) and HT-29 stem cells 
were treated with the chemotherapeutic drug 5-FU to assess sensitivity. Injections of 
the stem cells were also given to BALB/c mice to confirm tumor growth and 
characteristics. In addition, the effect of different concentrations of P. oleracea 
extract was tested on the growth of HT-29 and HT-29 stem cells, which was 
determined by the MTT method. The effects of P. oleracea extract on the expression 
of β-catenin, Notch1, and Notch2 in HT-29 cells were detected by RT-PCR and 
Western blotting. 
Results: The tumor volume of HT29 cells was two times larger than that of HT29 
stem cells. Treatment with P. oleracea extracts inhibited the proliferation of both 
HT-29 and HT-29 stem cells in doses from 0.07 - 2.25 μg/mL. Apoptosis of HT-29 
and HT-29 stem cells, as assessed by flow cytometry, was enhanced by the addition of 
P. oleracea extract. Finally, treatment with P. oleracea extracts significantly 
down-regulated the expression of the Notch1 and β-catenin genes in both cell types. 
Conclusion: This study shows that P. oleracea extract inhibits the growth of colon 
cancer stem cells in a dose-dependent manner. Furthermore, it inhibits the expression 
of the Notch1 and β-catenin genes. Taken together, this suggests that it may elicit its 
effects through regulatory and target genes that mediate the Notch signal transduction 
pathway.
xii 
xiii 
Key Words: Colon Cancer Stem Cells; Portulaca oleracea Extract; Notch Signal 
Transduction Pathway 
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1.0 Introduction and Study Background1  
1.1 Abstract 
Cancer stem cells are cells which have been reported to have the ability to 
self-differentiate and self-renew. In colon cancer, the cells have been shown to play a 
significant role in tumorigenesis, abnormal differentiation, recurrence, and metastasis 
of colon cancer. Additionally, research has shown that the cancer stem cells are 
insensitive to chemotherapy and immunotherapy, hence the need for an alternative 
therapy. The use of herbal medicines is seen as a viable alternative with reports 
indicating that P. oleracea extracts have the ability inhibit a number of different 
cancer cell types. However, the effectiveness of P. oleracea extracts in inhibiting 
colon cancer stem cells has not been investigated. Also, although it is known that 
dysregulations of the Notch signal transduction pathway play a significant role in the 
development of colon cancer stem cells, no study has been conducted to investigate 
the effects of P. oleracea extracts on Notch signal transduction pathway. Therefore, 
the purpose of this study was to determine if P. oleracea extracts can inhibit colon 
cancer stem cells, and if the effects observed are mediated by the Notch signal 
transduction pathway.  
                                                        
1 The material contained in this chapter was already submitted to Tumor Biology. 
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1.2 Introduction 
Colon cancer is a significant public health problem worldwide ranked as the 
fourth leading cause of cancer-related mortalities worldwide (S. Liu et al., 2015). The 
development, recurrence, and metastasis of colon cancer cells are mediated by colon 
cancer stem cells, a small proportion of tumor cells that can self-renew, infinitely 
proliferate, and have the potential for multi-directional differentiation. The stem cells 
must be inhibited in the initiating cells associated with carcinogenesis to maintain the 
growth of the tumor (Kucia et al., 2005). It was once believed that tumor stem cells 
only existed in hematological and lymphocytic malignancies; however, it is now 
known that tumor stem cells heavily influence all solid tumors (Patrawala et al., 2005; 
Setoguchi et al., 2004). 
Some cells present in human colon crypts can self-renew and differentiate. 
Mediated by a series of genes that maintain a dynamic balance in the colon, these 
stem cells play an important role in the regeneration and restoration of the organ 
(Dhawan, Ahmad, Srivastava, & Singh, 2011). External forces, such as mutations, can 
have long-term effects when they impact colon stem cells. During a prolonged period 
of time, oncogene mutations can accumulate thereby promoting the transformation of 
stem cells and the asymmetric division of stem cells and ultimately leading to the 
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production of colon cancer stem cells (Dhawan et al., 2011). Colon cancer stem cells 
have the same self-differentiation and self-renewal characteristics of normal colon 
stem cells; however, cancer stem cells play a role in tumorigenesis and abnormal 
differentiation (L Ricci-Vitiani, Pagliuca, Palio, Zeuner, & De Maria, 2008). In 
clinical practice, stem cells do not invade the tumor but rather are present during the 
earliest stages of colon cancer. Additionally, cancer stem cells are present only at the 
primary tumor site and do not appear to be involved in distant metastases. However, 
recent studies have indicated that colon cancer stem cells are important to the 
recurrence and metastasis of colon cancer (Dhawan et al., 2011; L Ricci-Vitiani et al., 
2008).  
Currently, many molecular markers can be used to identify and isolate colon 
cancer stem cells. The most commonly used molecular markers include CD133 and 
CD44, as well as CD24, epithelial-specific antigen (ESA), CD166, CD29, and 
leucine-rich repeat containing G protein-coupled receptor (Lgr) (Dalerba, Dylla, et al., 
2007; Kemper et al., 2012; O’Brien, Pollett, Gallinger, & Dick, 2007; Lucia 
Ricci-Vitiani et al., 2007; Todaro et al., 2007; Vermeulen et al., 2008). Most colon 
cancer stem cells have been reported to be insensitive to chemotherapy and 
immunotherapy, and these cells are thought to be involved in the development of 
resistance to chemotherapy (Dhawan et al., 2011). Taken together with their 
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important roles in many cancer processes, these cells may be an important target for 
the prevention and treatment of colon cancer (Dhawan et al., 2011).  
At present, there are no effective methods for the suppression of colon cancer 
stem cells. Previous studies have found that the foods used in traditional Chinese 
medicine can prevent and treat colon cancer; for example, extract from the edible 
vegetable P. oleracea has been shown to inhibit a number of different cancer cell 
types (H.-Y. Jin, Zhang, Wang, Xu, & Ding, 2012). However, at present no study has 
yet determined the effect of P. oleracea extract on colon cancer stem cells. 
Additionally, the Notch signal transduction pathway has been shown to be important 
for the development of colon cancer stem cells (H.-Y. Jin et al., 2012; Qiao & Wong, 
2009). Therefore, the purpose of this study was to determine if P. oleracea can inhibit 
colon cancer stem cells, and if the effects observed were mediated by the Notch 
signal transduction pathway.  
1.3 Study Background 
1.3.1 Colon Cancer: Epidemiology 
Colon cancer, also known as colorectal cancer, accounts for more than 9% of all 
the cases of cancers in the world (Haggar & Boushey, 2009) and the third most 
common type of cancer worldwide (Fitzmaurice et al., 2015). Epidemiological data 
have also shown that colon cancer is the fourth leading cause of cancer-related 
5 
 
mortalities worldwide (S. Liu et al., 2015). The cancer is common in both men and 
women with reports indicating that the cancer accounts for 9.4% of all cancer 
incidences in men and 10.1% in women (Haggar & Boushey, 2009). Therefore, colon 
cancer is a significant public health problem worldwide requiring appropriate and 
effective therapy.  
1.3.2 Colon Cancer: Causes and Risk Factors 
There are several factors which have been shown to be risk factors and/or causes 
of colon cancer. The factors are grouped into environmental, other health conditions 
and genetic factors as well as interactions between the genetic and environmental 
factors. Environmentally, obesity (Bardou, Barkun, & Martel, 2013), sedentary 
lifestyle (Durko & Malecka-Panas, 2014; Shen et al., 2014) and unhealthy dietary 
(Béliveau & Gingras, 2007; Myles, 2014) habits have been shown to increase the risk 
of colon cancer in both women and men.  
According to Bardou, Barkun, and Martel (2013), obesity leads to metabolic 
syndromes, insulin resistance and dysregulation of adipocytokines levels which 
results in increased risk of colon cancer. Through these mechanisms, obesity is also 
associated with poor cancer outcomes including recurrence ad metastasis of the 
cancers as well as increased mortalities (Bardou et al., 2013). Indeed, it has also been 
reported that hyperinsulinemia, due to obesity-associated type 2 diabetes mellitus, 
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plays a significant role in the pathogenesis and spread of colon cancer (Frezza, 2006). 
A systematic literature review of studies by Ma et al. (2013) also found that obesity is 
associated with up to 60% greater risk of colon cancer when compared to individuals 
with normal body mass index. Therefore, the available research evidence indicates 
that obesity does not only increase the risk of developing colon cancer by up to 60%, 
but is also associated with poor clinical outcomes of the cancer.  
Sedentary lifestyle is another environmental factor which has been associated 
with the risk of colon cancer. According to Shen et al. (2014), a sedentary lifestyle 
characterized by low levels of physical activity is associated with obesity and poor 
weight management which in turn increases the risk of colon cancer and results in 
poor clinical outcomes among patients with the cancer. Boyle, Fritschi, Heyworth and 
Bull (2011) also found that people who spent 10 or more years in sedentary work had 
twice the risk of colon cancer when compared to the people who did not spend any 
time in sedentary work. The Boyle et al. (2011) study also found that the association 
between sedentary lifestyle and colon cancer was independent of recreational 
physical activity. The findings demonstrate the significant role played by sedentary 
lifestyle in increasing the risk of developing colon cancer. The association can occur 
via obesity, where the sedentary lifestyle increases the body mass index of a person, 
or directly where the sedentary lifestyle results in colon cancer independent of body 
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weight and physical activity.  
Like sedentary lifestyle, unhealthy eating habits such as consumption of high- 
calorie food and food rich in fats can result in obesity which in turn increases the risk 
of developing colon cancer and/or complicates the clinical outcomes of the cancer 
(Myles, 2014). Research has also shown that high-fat contents in food disrupt the 
composition of the gut normal flora which in turn increase the risk of colon cancer 
(Zackular et al., 2013). Indeed, the Zackular et al. (2013) study established that 
patients with colon cancer have altered gut flora when compared to healthy patients. 
The study also found that the manipulation of gut flora in mice with antibiotics 
increased the number and size of the gut tumours. The findings suggest that 
disruption of the gut microbiota increases the risk and pathogenesis of colon cancer. 
Therefore, consumption of high-fat content foods which alters the gut microbiota 
increases the risk of colon cancer and may be associated with the pathogenesis, 
invasion, and metastasis of the cancer.  
In addition to these environmental factors, other factors such as alcohol 
consumption and tobacco smoking have also been reported to be significantly 
associated with colon cancer (Cho et al., 2015). It is known that consumption of 
alcohol and smoking cigarette are major risk factors for gastrointestinal cancers 
including colon cancer (Cho et al., 2015). Alcohol is a carcinogen (group 1 
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carcinogen) which has been shown to be a significant contributor to the risk of colon 
cancer (Tsong et al., 2007). Indeed, a study cited by Tsong et al. (2007) found that 
there is 30% higher risk of colon cancer in people who consume two alcoholic drinks 
per day compared to non-drinkers. Similarly, cigarette is a carcinogen which has been 
associated with the risk of colon cancer at a relative risk of 1.19 at 95% confidence 
interval (Limsui et al., 2010). Botteri et al. (2008) also found that ever-smokers are 
18% more likely to develop colon cancer compared to non-smokers. Research has 
also shown that the metabolites of cigarette such as cotinine, O-cresol sulfate, and 
hydroxycotinine are the carcinogens that induce colon cancer in cigarette smokers 
(Cross et al., 2014).  
In addition, certain health conditions such as gastrointestinal inflammation and 
high blood levels of insulin have also been associated with colon cancer. According to 
Terzić, Grivennikov, Karin and Karin (2010), the association between gastrointestinal 
inflammations such as inflammatory bowel disease and colon cancer is 
well-established. During inflammation, activated inflammatory cells produce reactive 
oxygen species (ROS) and reactive nitrogenous metabolites which cause DNA 
damage and mutations resulting in uncontrolled cell proliferation and cancer (Terzić 
et al., 2010). Therefore, gastrointestinal inflammation results in the production of 
ROS and reactive nitrogenous intermediates which induce DNA mutations in the 
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colon leading to colon cancer. High levels of insulin in blood has also been shown to 
increase the risk of colon cancer. According to Johnson and Gale (2010), insulin is a 
mitogenic hormone and overexpresses their receptors on the surface of cancer cells if 
present in high levels in the blood. Therefore, high level of insulin in blood acts as 
tumour growth factors which promote the development and spread of cancer cells. 
Increased levels of insulin in the blood, like the case in type 2 diabetes mellitus due to 
insulin resistance can, therefore, promote the development and spread of colon cancer 
cells.  
Genetically, research has shown that up to 10% of all the cases of colon cancer 
are hereditary conditions (Jackson-Thompson, Ahmed, German, Lai, & Friedman, 
2006). The mist common hereditary colon cancers are hereditary nonpolyposis colon 
cancer and familial adenomatous polyposis (Haggar & Boushey, 2009). Hereditary 
nonpolyposis colon cancer is caused by is due to mutations in genes that regulate 
DNA repair such as the MLH1 and MSH2 genes. Mutations in these genes (MLH1 
and MSH2 genes) results in hereditary nonpolyposis colon cancer, which accounts for 
approximately 2% to 6% of all the forms of colon cancer (Haggar & Boushey, 2009). 
Familial adenomatous polyposis is caused by mutations in the APC gene (a tumour 
suppressor gene) which occur in an autosomal dominant manner (Haggar & Boushey, 
2009).  
10 
 
Interactions between genetic and environmental factors also contribute to the risk 
of developing colon cancer. For instance, increased physical activity has been shown 
to interact with certain genes to influence the clinical outcome of the cancer (Marley 
& Nan, 2016). Indeed, it has been shown that the level of physical activity with colon 
cancer survival in patients diagnosed to be prostaglandin-endoperoxide synthase 
2-positive (PTGS2-positive) (Yamauchi et al., 2013). Similarly, Meyerhardt et al. 
(2009) found that physically active colon cancer patients with P27 expression had a 
68% lower mortality rates from the cancer compared to colon cancer patients who 
were physically inactive. In addition, further research has shown that the interaction 
between environmental factors such as alcohol consumption, obesity, intake of 
vitamin D and intake of polyunsaturated fatty acids have also been shown to 
influence the risk of colon cancer (Marley & Nan, 2016; Morikawa et al., 2013). 
1.3.3 Colon Cancer Stem Cells and Colon Cancer 
1.3.3.1 Differences between Colon Cancer Stem Cells and Colon Cancer Cells 
In addition to environmental and genetic factors, colon cancer stem cells also 
play a significant role in the development, recurrence and metastasis of colon cancer 
(Dhawan et al., 2011; L Ricci-Vitiani et al., 2008), hence the need to identify the stem 
cells for diagnosis and treatment. Cancer stem cells are a small sub-population of 
tumour cells with the ability to efficiently propagate cancer development and 
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pathogenesis (Puglisi, Tesori, Lattanzi, Gasbarrini, & Gasbarrini, 2013). Therefore, 
cancer stem cells can be defined as a small proportion of tumor cells, making 0.1to 
10% of tumour cells (Deonarain, Kousparou, & Epenetos, 2009), that can self-renew, 
infinitely proliferate, and have the potential for multi-directional differentiation.  
Cancer cells are abnormal cells capable of differentiating and proliferating 
indefinitely and can invade surrounding tissues and metastasize to distant organs 
(Sitas et al., 2006). The cancer cells can either be benign or malignant. Benign cancer 
cells are tumours that remain confined to the original site of location without 
invading the surrounding tissues or metastasizing to distant organs. Malignant 
tumours are cancer cells with abnormal and unregulated proliferation and 
differentiation with the ability to invade surrounding tissues and metastasize to distant 
organs (Sitas et al., 2006). On the other hand, cancer stem cells are cells within 
benign or malignant tumours with the same characteristics as normal stem cells (can 
give rise to new cells) (Magee, Piskounova, & Morrison, 2012).  
Since cancer stem cells form a small sub-population of tumour cells, their 
identification can be challenging. However, comparison of other cancer stem cells 
and cancer cells have revealed some significant differences which can be used to 
identify and isolate colon cancer stem cells. For instance, it has been reported that 
cancer cells and cancer stem cells can be distinguished based on their sensitivity to 
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chemotherapeutic agents where cancer stem cells have been found to be more 
insensitive to the agents than cancer cells (Vinogradov & Wei, 2012). The expression 
of CD133 and CD44 has also been utilised as a basis of differentiating cancer cells 
from cancer stem cells. For instance, it has been shown that cancer stem cells have 
higher expression of CD133 and CD44 compared to cancer cells (Guo, 2012; Nagata 
et al., 2011). Other reports have also established that cancer cells take up more 
Hoechst33342 stain and have a higher growth rate compared to cancer cells (Gao, 
Geng, Kvalheim, Gaudernack, & Suo, 2009; Toloudi et al., 2014).  
1.3.3.2 Role of Colon Cancer Stem Cells in Cancer Development, Recurrence and 
Metastasis  
There is research evidence to show that colon cancer stem cells are associated 
with development (Abdul Khalek, Gallicano, & Mishra, 2010), recurrence 
(Ramasamy, Ayob, Myint, Thiagarajah, & Amini, 2015) and metastasis (Basu, Haase, 
& Ben-Ze’ev, 2016) of colon cancers. When compared to normal stem cells, cancer 
stem cells has no restricted or regulated rate of proliferation and have a slow rate of 
cycling which plays a significant role in tumour recurrence and initiating resistance to 
chemotherapy and radiotherapy (Moore & Lyle, 2011; Pannuti et al., 2010). In 
addition, cancer stem cells have the ability to initiate new tumours hence plays a 
significant role in metastatic colorizations (Hanahan & Weinberg, 2011). 
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1.3.3.3 Properties of Colon Cancer Stem Cells   
The main properties of colon cancer stem cells include self-renewal potential, 
ability to differentiate into diverse cell populations and ability to balance and 
modulate the processes of self-renewal and differentiation (Garza-Treviño, 
Said-Fernández, & Martínez-Rodríguez, 2015). Self-renewal refers to the ability of 
the colon cancer stem cells synthesize new cells with the same ability to proliferate, 
expand and differentiate as the parental cells thereby maintaining a pool of the stem 
cell (Garza-Treviño et al., 2015). The mechanisms utilised for the self-renewal of the 
colon cancer stem cells, such as the Wnt/β-catenin and Notch pathways, makes use of 
proto-oncogenes. In addition, the self-renewal pathway of colon cancer stem cells is 
regulated by the sonic hedgehog (Hh) signaling pathway, a pathway commonly 
reported in multiple myeloma (Varnat et al., 2009). Research has shown that the 
self-renewal of colon cancer stem cells is promoted by the Wnt pathway and the 
prevention of the β-catenin-dependent transcription (Ong, Vega, & Houchen, 2014). 
Additionally, the Notch receptors pathway have also been reported to promote 
the self-renewal of colon cancer stem cells (Ong et al., 2014). In the Notch pathway, 
the DLL4 genes stimulate the Notch receptors on adjacent cells and in combination 
with the effects of β-catenin promotes the self-renewal of the cancer stem cells by 
directing an immature transcription profile (Garza-Treviño et al., 2015). However, the 
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self-renewal pathways are inhibited by BMP4 genes which bind BMP receptors 
leading to interference with the Wnt pathway and thus promote cell differentiation. 
The process of differentiation has also been reported to be inhibited by hepatocyte 
growth factor (HGF) leading to the maintenance of the cells in a stem-cell state (Ong 
et al., 2014).   
Cancer stem cells also have the ability into differentiate to diverse cell 
populations (Garza-Treviño et al., 2015). That is, the stem cells have the ability to 
differentiate into a heterogeneous progeny of cells that can undergo progressive 
diversification and specialization following self-renewal. The cells of this 
differentiation are specialized to carry out certain unique physiological functions 
(Dalerba, Cho, & Clarke, 2007). However, histopathological studies of colon cancers 
have indicated that the cells are relatively undifferentiated containing higher 
proportions of colon cancer stem cells than more differentiated cancer cells (Ashley, 
Yeung, & Bodmer, 2013; Merlos-Suárez et al., 2011). The undifferentiated colon 
cancer cells have worse clinical prognosis compared to differentiated cancer cells 
(Merlos-Suárez et al., 2011).  
Homeostatic control where the cells have the ability to balance and modulate the 
processes of self-renewal and differentiation is also a key property of cancer stem 
cells (Garza-Treviño et al., 2015). Through research, it has been established that 
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differentiated intestinal epithelial cells reside in the intestinal crypts as repeats of 
stem cells containing leucine and B lymphoma Mo-MLV insertion region 1 homolog 
(Bmi-1) or G protein-coupled receptor 5 (Lgr5) (Tian et al., 2011). The Bmi-1 AND 
Lgr5 are used to maintain the capacity of tissues to regenerate (Tian et al., 2011). The 
intestinal cells that express Lgr5 undergo active proliferation and very sensitive to 
stimulatory effects of Wnt and Dkk1-mediated Wnt inhibition (Tian et al., 2011). On 
the other hand, intestinal cells that express Bmi-1 are less sensitive to environmental 
stressors and are, therefore, not affected by the Wnt modulation. The 
Bmi-1-expressing intestinal cells are normally quiescent, only giving rise to cell 
progeny under certain conditions (Yan et al., 2012). The Wnt proteins and the Notch 
pathway has been reported to play a significant role in maintaining cancer stem cells 
hemostasis by providing signals required for the maintenance of the phenotype of 
colon cancer stem cells in the tumour mass (Garza-Treviño et al., 2015). 
 
1.3.3.4 Markers of Colon Cancer Stem Cells  
Colon surface antigens on the surface of the stem cells have been identified as the 
markers for colon cancer stem cells. According to Deonarain et al. (2009), these 
antigens are not identified based on their overexpression on typical tumour cells, but 
on their presence in a population of cells with stem cell-like properties. However, the 
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identification of the cancer stem cell antigen has been challenging due to their 
variable expression on cancer stem cells and frequent co-expression in normal stem 
cells (Deonarain et al., 2009). Currently, many molecular markers have been 
discovered for the identification and isolation of colon cancer stem cells.  
The most commonly used molecular markers include CD133 and CD44, as well 
as CD24, epithelial-specific antigen (ESA), CD166, CD29, and Lgr (Dalerba, Dylla, 
et al., 2007; Kemper et al., 2012; O’Brien et al., 2007; Lucia Ricci-Vitiani et al., 2007; 
Todaro et al., 2007; Vermeulen et al., 2008). Most colon cancer stem cells have been 
reported to be insensitive to chemotherapy and immunotherapy, and these cells are 
thought to be involved in the development of resistance to chemotherapy (Dhawan et 
al., 2011). Taken together with their important roles in many cancer processes, these 
cells may be an important target for the prevention and treatment of colon cancer 
(Dhawan et al., 2011). 
1.3.4 Colon Carcinogenesis  
The transformation of normal cells to cancer cells requires six hallmarks; 
self-sufficiency in signals required for growth, the potential for unlimited replication, 
insensitivity to snit-growth signals, ability to evade apoptosis, tissue invasion and 
sustained angiogenesis (Garza-Treviño et al., 2015). Initially, there must be genetic 
defects within the cell that result in DNA instability and then inactivation of tumour 
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suppressor genes. This results in uncontrolled cell division, differentiation, and 
self-renewal leading to cancer development (Garza-Treviño et al., 2015).  
In colon cancer, the transformation of normal intestinal cells to colon cancer cells 
begins with an increase in the intracellular β-catenin in normal colon epithelial tissue. 
This results in prolonged activation of the Wnt pathway, stabilization of β-catenin, 
and activation of the C-terminal binding protein 1 (CtBP1) (Garza-Treviño et al., 
2015). Additionally, there is inactivation of the APC gene which initiates adenoma 
while the nuclear localization and activation of β-catenin promote the activation of 
the formed adenoma to carcinoma (Phelps et al., 2009). The progression of colon 
tumours is driven by mutations in phosphatidylinositol 3-kinase (PIK3CA) and 
transforming growth factor-beta receptor (TGFBR) genes (Armaghany, Wilson, Chu, 
& Mills, 2012). In addition to these mechanisms, research has also established that 
normal stem cells, instead of progenitor and differentiated cells, are also involved in 
the initiation of colon cancers of cellular origin (Armaghany et al., 2012).  
1.3.5 Colon Cancer Stem Cells in Colon Carcinogenesis  
Cancer stem cells are transformed to more malignant phenotypes during the 
process of primary cancer progression via three main pathways; microsatellite 
instability (defects in DNA mismatch repair), chromosomal instability, and CpG 
island methylator phenotype pathways (Pino & Chung, 2010). These carcinogenic 
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pathways cooperate leading to the activation of different downstream signaling 
effectors such as mitogen-activated protein kinases (MAPKs), PI3K/Akt/molecular 
target of rapamycin (mTOR) and nuclear factor-kappaB (NF-kB) conferring 
high-level self-renewal ability to the cells (Birnie et al., 2008; Chiba et al., 2008; S. 
Ma, Lee, Zheng, Chan, & Guan, 2008; Mimeault, 2012; Shiras et al., 2007; 
Venugopal et al., 2012; Wang et al., 2012). In addition to transforming themselves to 
more malignant phenotypes, colon cancer stem cells also initiate the development, 
recurrence, and metastasis of colon cancers (Dhawan et al., 2011; L Ricci-Vitiani et 
al., 2008). 
1.3.6 Chemotherapy and Chemoresistance  
Colon cancer is primarily managed with chemotherapy regiments of “5 
fluorouracil (5FU), oxaliplatin and/or leucovorin or 5-FU, leucovorin and irinotecan 
(FOLFIRI)” (Garza-Treviño et al., 2015, p.2). The drugs display anti-cancer 
properties by inducing oxidative damage of the cancer cells. However, the 
chemotherapy regimen has been reported to be ineffective leading to treatment 
failures in 90% of metastatic colon cancer and this has been attributed to 
chemoresistance (Zhao, Butler, & Tan, 2013). The oxidative damage of the cancer 
cells increases the glycolysis of the cells resulting in high levels of the antioxidant 
NADPH, which can be associated with chemoresistance (Wu, Calcagno, & Ambudkar, 
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2008).  
Colon cancer stems also displays chemoresistance by expressing HIF-1α which 
decreases the pro-apoptotic signaling. The expression of HIF-1α induces the 
expression of decoy receptors like DcR2 which competes for the pro-apoptotic 
signaling factors such as the tumor necrosis factor-related apoptosis inducing ligand. 
This reduces the signaling through the apoptosis-inducing receptors and, therefore, 
attenuates apoptosis thereby allowing cells to tolerate high levels of chemotherapeutic 
agents (Chen et al., 2009; Flamant, Notte, Ninane, Raes, & Michiels, 2010; Sullivan 
& Graham, 2009; Wen et al., 2010). Indeed, there is research evidence to show that 
most colon cancer stem cells are insensitive to chemotherapy and immunotherapy, 
leading to the development of resistance to chemotherapy (Dhawan et al., 2011).  
1.3.7 Treatment Implications of Colon Cancer Stem Cells 
Colon cancer stem cells play a significant role in the development, recurrence, 
and metastasis of colon cancer and can, therefore, be an important target for the 
prevention and treatment of colon cancer (Dhawan et al., 2011). The cancer stem cells 
are insensitive to chemotherapy hence the need for alternative therapy. Research has 
shown that immunotherapy with antibodies can be utilised as an alternative therapy. 
For instance, studies have shown that colon cancer stem cells that are insensitive to 
5FU can be made sensitive by the use of interleukin-4 blocking antibody (Todaro et 
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al., 2007; Todaro, Perez Alea, Scopelliti, Medema, & Stassi, 2008). Similarly, it has 
been demonstrated that the use of anti- epiregulin, epidermal growth factor family 
(anti-EREG) antibodies is an effective immunotherapy against colon cancer 
metastasis (Kobayashi et al., 2012). Therefore, there is research evidence to 
demonstrate the effectiveness of immunotherapy against colon cancer stem cells. 
However, immunotherapy is an expensive alternative to chemotherapy due to the high 
cost of producing, storing and transporting the antibodies (Lynch & Murphy, 2016).  
Alternatively, nanotechnology can also be utilised to suppress colon cancer stem 
cells which are resistant to chemotherapy. For instance, siRNA-mediated knockdown 
of the drug efflux protein MDR1 (the protein is overexpressed in colon cancer stem 
cells) has been described as a nanotechnology method of overcoming 
chemoresistance by the colon cancer stem cells (Liu et al., 2009). However, 
nanotechnology is also an expensive therapy which cannot be afforded by most colon 
cancer patients (Kim, Buddolla, & Lee, 2016). Therefore, a more affordable and 
effective alternative is necessary to overcome the chemoresistance of colon cancer 
stem cells in the treatment of colon cancers.  
1.3.8 Portulaca oleracea Extracts for the Inhibition of Colon Cancer Stem Cells 
As discussed earlier, the chemoresistance of colon cancer stem cells, despite their 
significant role in the development, recurrence, and metastasis of colon cancers, can 
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be overcome by immunotherapy  (Kobayashi et al., 2012) and nanotechnology (Liu 
et al., 2009). However, these therapies are expensive and may not be affordable to 
many colon cancer patients(Kim et al., 2016; Lynch & Murphy, 2016). Therefore, a 
more affordable but effective alternative is necessary to overcome the 
chemoresistance. The use of medicinal plants has been utilised as an affordable 
alternative for cancer therapy and can also be utilised to overcome the 
chemoresistance of colon cancer stem cells. For instance, a study by Min, Lim, Kim, 
Kim, and Kim (2015) found that the leaves of Sasa quelpaertensis can inhibit colon 
cancer stem cells and influence gene expression related to stem cell development. In 
another study, Kumar, Kumar, Raina, Agarwal and Agarwal (2014) found that grape 
seed extract can inhibit the effect of colon cancer stem cells. P. oleracea extracts, a 
traditional Chinese medicine can prevent and treat colon cancer. Extracts of the plant 
have been to inhibit a number of different cancer cell types (H.-Y. Jin et al., 2012). 
However, at present no study has yet determined the effect of P. oleracea extract on 
colon cancer stem cells. Therefore, the purpose of this study was to determine if P. 
oleracea can inhibit colon cancer stem cells, and if the effects observed were 
mediated by the Notch signal transduction pathway.  
1.4 Aims of the Study 
Colon cancer stem cells have the ability to self-differentiate and self-renew and 
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play a significant role in tumorigenesis and abnormal differentiation (L Ricci-Vitiani 
et al., 2008). Although the stem cells do not invade tumors, they are present during 
the early stages of colon cancer development and have been shown to play a 
significant role in the recurrence and metastasis of colon cancer (Dhawan et al., 2011; 
L Ricci-Vitiani et al., 2008). In addition, research has shown that most cancer stem 
cells are insensitive to chemotherapy and immunotherapy and contributes to the 
development of resistance to chemotherapy (Dhawan et al., 2011). Despite the 
significant role played by the stem cells in the pathogenesis of cancers and resistance 
to chemotherapy, there are no effective methods for the suppression of colon cancer 
stem cells currently.  
However, previous studies have found that the foods used in traditional Chinese 
medicine can prevent and treat colon cancer; for example, extract from the edible 
vegetable P. oleracea has been shown to inhibit a number of different cancer cell 
types (H.-Y. Jin et al., 2012). The effectiveness of the P. oleracea vegetable in 
inhibiting colon cancer stem cells has, however, not been investigated. In addition, 
research has shown that Notch signal transduction pathway plays a significant role in 
the development of colon cancer stem cells (H.-Y. Jin et al., 2012; Qiao & Wong, 
2009). Therefore, dysregulation of the Notch signal transduction pathway by this 
vegetable can it the development of colon cancer stem cells. As a result, the main 
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purpose of this study was to determine if P. oleracea extracts can inhibit colon cancer 
stem cells, and if the effects observed were mediated by the Notch signal transduction 
pathway. This was accomplished by meeting the following general and four specific 
objectives. 
1.4.1 General Objective 
To investigate the role and mechanism of P. oleracea extracts in inhibiting the 
proliferation of colon cancer stem cells. 
1.2.2 Specific Objectives 
• To investigate the differences between colon cancer cells (HT29 cells) and 
colon cancer stem cells (HT29 stem cells) 
• To determine if P. oleracea extracts can inhibit colon cancer stem cells 
• To investigate the dysregulations of the Notch signal transduction pathway in 
P. oleracea extracts-mediated inhibition of colon cancer stem cells 
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2.0 Chapter 1: Differences between HT29 Cancer Cells and HT29 Stem Cells 
2.1 Abstract 
Identification of the unique features of cancer stem cells that can be used to 
differentiate them from cancer cells is significant to the management of cancers due 
to their association with cancer development, recurrence, and metastasis. This study 
used HT29 colon cancer cells and HT29 colon cancer stem cells to compare the 
characteristics of the two cell lines. The cells were cultured in RPMI-1640 medium 
with 10% fetal bovine serum (FBS) and then flow cytometric analysis of cd133 and 
cd44, chemotherapy drug sensitivity assay, Hoechst 33342 staining, proliferation 
assessment and in vivo tumorigenesis assay carried out. The results showed that the 
HT29 colon cancer stem cells have a significantly higher Hoechst33342 staining, 
significantly increased expression of CD133 and CD44 markers, significantly faster 
growth and have a lower sensitivity to chemotherapeutic drug 5-FUdrug compared to 
the HT29 colon cancer cells. These characteristics can be used in clinical practice to 
differentiate colon cancer stem cells from colon cancer cells for diagnostic purposes.  
All institutional and national guidelines from Chinese Association for Laboratory 
Animal Science for care and use of laboratory animals were followed.2 
                                                        
2 The material contained in this chapter was already submitted to Tumor Biology. 
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2.2 Introduction  
There is research evidence to show that colon cancer stem cells are associated 
with the development (Abdul Khalek et al., 2010), recurrence (Ramasamy et al., 2015) 
and metastasis (Basu et al., 2016) of colon cancers. These cells form a small 
sub-population of tumour cells with the ability to efficiently propagate cancer 
development and pathogenesis (Puglisi et al., 2013). Therefore, cancer stem cells can 
be defined as a small proportion of tumor cells, making 0.1to 10% of tumour cells 
(Deonarain et al., 2009), that can self-renew, infinitely proliferate, and have the 
potential for multi-directional differentiation.  
On the other hand, cancer cells are abnormal cells capable of differentiating and 
proliferating indefinitely and can invade surrounding tissues and metastasize to 
distant organs (Sitas et al., 2006). The cancer cells can either be benign or malignant. 
Benign cancer cells are tumours that remain confined to the original site of location 
without invading the surrounding tissues or metastasizing to distant organs. 
Malignant tumours are cancer cells with abnormal and unregulated proliferation and 
differentiation with the ability to invade surrounding tissues and metastasize to distant 
organs (Sitas et al., 2006). On the other hand, cancer stem cells are cells within 
benign or malignant tumours with the same characteristics as normal stem cells (can 
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give rise to new cells) (Magee et al., 2012).  
Since cancer stem cells form a small sub-population of tumour cells, their 
identification can be challenging. However, comparison of other cancer stem cells 
and cancer cells have revealed some significant differences which can be used to 
identify and isolate colon cancer stem cells. For instance, it has been reported that 
cancer cells and cancer stem cells can be distinguished based on their sensitivity to 
chemotherapeutic agents where cancer stem cells have been found to be more 
insensitive to the agents than cancer cells (Vinogradov & Wei, 2012). The expression 
of CD133 and CD44 has also been utilised as a basis for differentiating cancer cells 
from cancer stem cells. For instance, it has been shown that cancer stem cells have 
higher expression of CD133 and CD44 compared to cancer cells (Guo, 2012; Nagata 
et al., 2011). Other reports have also established that cancer cells take up more 
Hoechst33342 stain and have a higher growth rate compared to cancer cells (Gao et 
al., 2009; Toloudi et al., 2014). 
Currently, many molecular markers can be used to identify and isolate colon 
cancer stem cells. The most commonly used molecular markers include CD133 and 
CD44, as well as CD24, epithelial-specific antigen (ESA), CD166, CD29, and 
leucine-rich repeat containing G protein-coupled receptor (Lgr) (Dalerba, Dylla, et al., 
2007; Kemper et al., 2012; O’Brien et al., 2007; Lucia Ricci-Vitiani et al., 2007; 
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Todaro et al., 2007; Vermeulen et al., 2008). Most colon cancer stem cells have been 
reported to be insensitive to chemotherapy and immunotherapy, and these cells are 
thought to be involved in the development of resistance to chemotherapy r (Dhawan 
et al., 2011). Taken together with their important roles in many cancer processes, 
these cells may be an important target for the prevention and treatment of colon 
cancer (Dhawan et al., 2011).   
Indeed, the identification of cancer stem cells has been shown to be critical in the 
management of cancers because inhibiting such stem cells will reduce the risk of 
cancer development and recurrence (Huang, Cheng, Guryanova, Wu, & Bao, 2010). 
Therefore, it is important to understand the differences between colon cancer cells 
and colon cancer stem cells for the identification of the later. An example of cancer 
cell lines is the HT29 cancer cells which are derived from human colon carcinoma 
cells (Schreier et al., 2014). The HT29 stem cells are examples of cancer stem cells 
derived from human colon carcinoma cells (Yeung, Gandhi, Wilding, Muschel, & 
Bodmer, 2010). In this study, the HT29 cancer cells and HT29 stem cells were used to 
investigate the differences in the characteristics of cancer cells and cancer stem cells.  
2.3 Materials and Methods 
2.3.1 Cell Culture  
The colon cancer cells and colon cancer stem cells were cultured and separated 
44 
 
as previously described (Todaro et al., 2007; Vermeulen et al., 2008). Briefly, the cells 
of the HT29 human colon cancer cell line were cultured in RPMI-1640 medium with 
10% fetal bovine serum (FBS) until they reached 90% confluence, at which point the 
cells were collected. Next, the cells were centrifuged and the supernatant was 
removed. The cells were re-suspended in serum-free DMEM/F12 medium 
(containing 20 ng/mL epidermal growth factor, 10 ng/mL basic fibroblast growth 
factor, 5 µg/mL insulin, 0.4% bovine serum albumin, and 2% B27), counted, and then 
cultured in 6-pore suspension culture plates at a concentration of 1×104 cells/mL at 
37°C and 5% CO2. After culturing for 3-7 days, the growth of the glomus cells could 
be visualized. After 30 minutes at 37°C, the cells precipitated, and the supernatant 
was removed (containing a small amount of individual cells and cell debris). 
Serum-free DMEM/F12 was added for an expanded culture. After centrifuging the 
glomus cells, digestion and passage, as well as cultivation, was performed for several 
generations to purify the cells. Finally, the cells were collected for drug sensitivity 
testing, proliferation assays, flow cytometry, and Hoechst 33342 staining, as 
indicated.  
2.3.2 Flow Cytometric Analysis of CD133 and CD44 
HT-29 cells and HT-29 stem cells were first scattered and digested with 
EDTA-containing trypsin, before quickly diluting and mixing with DMEM/F12 
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medium. After centrifuging at 1500 rpm for 5 min, the supernatants were removed 
and the cells were washed twice with PBS. Cells were re-suspended in 300 µL of 
PBS and a homogenous mixture was obtained before each cell suspension was 
divided into three separate suspensions, each consisting of 100 µL, which received 
different treatments. The first was used as a blank/control. The second was treated 
with 10 µL of anti-CD44-APC in the dark for 15 minutes at 4°C. The third was 
treated with 10 µL of Fcr Block for 15 minutes at 4°C, and then received 10 µL of 
anti-CD133-APC for 20 minutes at 4°C. The third was treated with 10 µL of Fcr 
Block for 15 minutes at 4°C, and then received 10 µL of both anti-CD133-APC and 
anti-CD44-APC for 20 minutes at 4°C (all procedures were carried out in the dark), 
before washing with PBS. All cells were re-suspended in 400 µL of PBS and then 
used for flow cytometry experiments to detect expression of the surface markers 
CD44 and CD133.  
2.3.3 Chemotherapy Drug Sensitivity Assay 
HT-29 cells and HT-29 stem cells were plated in 96-well cell culture plates at a 
concentration of 5000 cells/well. After cell adherence was noted, the 
chemotherapeutic drug 5-Fu (Fluorouracil) was added at different concentrations for 
72 hours (each concentration was tested in triplicate) and 20 mL of MTT solution was 
added. The medium was discarded after four hours and 150 µL of DMSO was added 
46 
 
and mixed with an oscillating movement. An optical density (OD) of 570 nm 
wavelength was used as a quick approximation of cell abundance in cell culture. And 
the IC50 values (the half maximal inhibitory concentration) were calculated to 
determine drug efficacy.  
2.3.4 Hoechst 33342 Staining 
HT-29 cells and HT-29 stem cells were first scattered and digested with 
EDTA-containing trypsin, before quickly diluting and mixing with DMEM/F12 
medium. After washing twice with PBS, the cells were re-suspended with PBS, 
mixed and incubated at 37°C for 2-3 hours. 500µl of Hoechst 33342 was added to the 
cultivated cells at a final concentration of 2 µg/mL and incubated at 37°C and for 10 
min. Cells were washed 3 times with PBS followed by 400 mesh screen filtration and 
analysis by flow cytometry. Heochst33342 dye excites with a krypton laser: the 
wavelength of excitation used was 352 nm with an expected emission wavelength 
was 400-500 nm (blue). 
2.3.5 Proliferation Assessment of HT-29 Colon Cancer Stem Cells and HT-29 
Colon Cancer Cells 
HT-29 cells and HT-29 stem cells were scattered and digested with 
EDTA-containing trypsin into single cell suspensions, and 1640 medium containing 
10% serum was quickly added to stop the digestion. After washing twice with PBS, 
the cells were re-suspended with PBS, mixed, and pipetted into 6-well plates. Cells 
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were cultured for 96 hours, cell growth was recorded, and photographs were taken 
with Zeiss inverted microscope.  
2.3.6 In Vivo Tumorigenesis Assay of HT-29 Colon Cancer Stem Cells and HT-29 
Colon Cancer Cells 
Bilateral stem cell injections were performed in the subscapularis of BALB/c 
mice, and the inguinal and axillary nodal status of HT29 stem cells and HT29 cells 
were noted with respect to tumorigenesis. A total of 20 average body weight of 20g, 
female BALB/c nude mice were used for each cell line. The first group was set as 
negative control. The second group was treated with Xeloda as a positive control. The 
third, the fourth and the fifth group were enhanced with resveratrol in the dose of 
50mg, 100mg, and 200mg respectively. The BALB/c mice' physical conditions were 
observed after injecting the stem cells and the experiment was ended by death or by 
the presence of a tumor with a diameter over 20 mm. Autopsies were performed to 
determine tumorigenesis in specific locations of the animal’s body and photographs 
were taken. Tumor incidence was calculated at each location of interest. Calculations 
of tumor volume and the growth rate were performed according to the following 
formulas:  
Tumor volume (mm3) = 1 / 2ab2 (where a = tumor diameter and b is the tumor minor 
diameter)  
Tumor growth rate = (measurement of tumor size at the time point – starting tumor 
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size) / starting tumor size. 
2.3.7 Statistical Analysis  
 All the experimental data were analyzed using SPSS statistical software version 
13.0 (IBM, Chicago, IL). A confidence interval of 95% was used and, therefore 
p-values of less than 0.05 were considered statistically significant.  
2.4 Results  
After serum-free cultivation, HT-29 colon cancer cells formed spindle-shaped 
cells, while HT-29 colon cancer stem cells showed spherical growth(Figure 1.1). 
After staining with Hoechst33342, the nuclei of HT29 colon cancer cells showed 
significantly less staining compared to the HT-29 colon cancer stem cells (Figure 
1.2). The positive expression rate of CD133 and CD44 in HT-29 cells was 44.6% and 
0.6%, respectively (Figure 1.3A). Conversely, the expression rate of CD133 and 
CD44 in cultured and purified HT-29 stem cells was 92.6% and 97.8%, respectively, 
and was significantly increased (p <0.001) compared to HT-29 colon cancer cells 
(Figure 1.3B). Additionally, results of the in vivo experiments showed that HT-29 
stem cells grew significantly faster than the HT-29 cells. Moreover, the volume of 
tumors formed by HT-29 cells was twice as large as those formed by HT-29 stem 
cells (Figure 1.4; p <0.05). In contrast, the growth rate of HT-29 cells was slow 
(Figure 1.4), and a continuous measurement data comparisons analysis revealed that 
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the difference was statistically significant (p < 0.001). Finally, the results of a drug 
sensitivity assay for the chemotherapeutic drug 5-FU showed that the IC50 of HT-29 
cells was 1.394 µg/mL, compared to 13.087 µg/mL in HT-29 stem cells (Figure 
1.5).
Figure 2.1: Proliferation Assessment of HT-29 Colon Cancer Stem Cells and 
HT-29 Colon Cancer Cell. In vitro Proliferation Assessment showed HT-29 stem 
cell’s proliferative activity dramatically increased after 48 hours. Magnification 100X 
Scale bar 10 micron. 
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Figure 2.2: Hoechst33342 staining for HT-29 cells (A) and HT-29 stem cells (B). 
Representative images are shown of Hoechst33342 staining for HT-29 cells (A) and 
HT-29 stem cells (B). Magnification was 400x for both, and scale bar = 20 µm.  
 
Figure 2.3: Flow Cytometric Analysis of CD133 and CD44 in HT-29 cells (A) and 
HT-29 stem cells (B).  
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Figure 2.4: In Vivo Tumorigenesis Assay of HT-29 Colon Cancer Stem Cells and 
HT-29 Colon Cancer Cells 
 
 
Figure 2.5: 5-FU Drug Sensitivity Assay for HT-29 Colon Cancer Stem Cells and 
HT-29 Colon Cancer Cells 
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2.5 Discussion 
In this study, stem cells were isolated from tumor cells by culturing them in 
serum-free medium. Tumor cells cannot grow in these conditions, whereas colon 
cancer stem cells have the ability to auto-synthesize (Al-Hajj, Wicha, 
Benito-Hernandez, Morrison, & Clarke, 2003; Kondo, Setoguchi, & Taga, 2004). The 
results showed spherical growth of the isolated HT-29 stem cells and staining with 
Hochest33342 revealed a phenomenon in which dye was excluded from the nuclear 
compartments. In addition, it was observed that there is a positive expression of 
CD133 and CD44, at 92.6% and 97.8% respectively, suggesting that these were 
correctly identified as colon cancer stem cells. Importantly, HT-29 stem cells were 
much less sensitive to 5-FU in this study than HT-29 cells: the IC50 of HT-29 cells 
was 1.394 µg/mL, compared to 13.087 µg/mL in HT-29 stem cells. These findings 
suggest that at conventional doses, colon cancer stem cells are resistant to 
chemotherapeutic drugs. Similar results were previously reported by Reya, Morrison, 
Clarke and Weissman (2001). Taken together, the results suggest that isolated HT-29 
stem cells had the general characteristics of colon cancer stem cells.  
Previously, it had been shown that colon cancer stem cells play an important role 
in the occurrence, development, recurrence, and metastasis of colon cancer, leading to 
the hypothesis that they may be an important target for cancer prevention and 
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treatment (Kanwar, 2012). Unfortunately, colon cancer stem cells are insensitive to 
chemotherapy drugs, such as 5-FU (Dhawan et al., 2011), and the toxicity associated 
with the chemotherapeutic treatment of these cells is high (Han, Shi, Gong, Zhang, & 
Sun, 2013; Vinogradov & Wei, 2012). Therefore, it is of great importance to explore 
new methods to inhibit colon cancer stem cells. This study explored the use of P. 
oleracea extracts, as a new method to inhibit colon cancer stem cells. 
2.6 Conclusion 
In conclusion, this study established that there are significant differences between 
HT29 colon cancer stem cells and HT29 colon cancer cells. The HT29 colon cancer 
stem cells have a significantly higher Hoechst33342 staining, significantly increased 
expression of CD133 and CD44 markers, significantly faster growth and have a lower 
sensitivity to chemotherapeutic drug 5-FUdrug compared to the HT29 colon cancer 
cells. These characteristics can be used in clinical practice to differentiate colon 
cancer stem cells from colon cancer cells for diagnostic purposes. 
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3.0 Chapter 2: The Effects of P. oleracea Extracts on HT-29 Stem Cells and HT-29 
Cells  
3.1 Abstract 
Novel cancer therapies that target cancer stem cells, which has a low insensitivity 
to chemotherapeutics, so as to inhibit their proliferation or induce their apoptosis is 
significant to the management of cancer development, invasion, recurrence, and 
metastasis. P. oleracea extract is of potential value in inhibiting the proliferation of 
cancer stem cells because studies have shown that to inhibit cancer cells. However, 
no study has investigated the effect of P. oleracea extracts on the proliferation and 
apoptosis of colon cancer stem cells. This study investigated the effect of ethanol 
extracts of P. oleracea on the proliferation and apoptosis of HT-29 cells and HT-29 
stem cells. Ethanol extracts of the medicinal plant were added to the cultured cells 
and the cell proliferation and apoptosis were assessed. The study found that P. 
oleracea extracts can inhibit the proliferation and increases the apoptosis of colon 
cancer stem cells at the cellular level in a dose-dependent manner. These results 
provide a new basis for the prevention and treatment of colon cancer at the level of 
colon cancer stem cells using P. oleracea extracts.3 
                                                        
3 The material contained in this chapter was already submitted to Tumor Biology. 
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3.2 Introduction 
Colon cancer, also known as colorectal cancer, is a significant public health 
problem and has been reported to account for more than 9% of all the cases of 
cancers in the world (Haggar & Boushey, 2009) and the third most common type of 
cancer worldwide (Fitzmaurice et al., 2015). Epidemiological data have also shown 
that colon cancer is the fourth leading cause of cancer-related mortalities worldwide 
(S. Liu et al., 2015). The cancer is common in both men and women with reports 
indicating that the cancer accounts for 9.4% of all cancer incidences in men and 
10.1% in women (Haggar & Boushey, 2009).  
Several risk factors including environmental factors such as obesity (Bardou et 
al., 2013), sedentary lifestyle (Durko & Malecka-Panas, 2014; Shen et al., 2014) and 
unhealthy dietary habits (Béliveau & Gingras, 2007; Myles, 2014) as well as other 
health conditions Terzić, Grivennikov, Karin and Karin (2010) and genetic factors 
(Jackson-Thompson et al., 2006) have been shown to increase the risk of colon cancer 
in both women and men. In addition to environmental and genetic factors, colon 
cancer stem cells also play a significant role in the development, recurrence and 
metastasis of colon cancer (Dhawan et al., 2011; L Ricci-Vitiani et al., 2008), hence 
the need to inhibit the stem cells for effective colon cancer therapy. 
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Currently, colon cancer is primarily managed with chemotherapy regiments of “5 
fluorouracil (5FU), oxaliplatin and/or leucovorin or 5-FU, leucovorin and irinotecan 
(FOLFIRI)” (Garza-Treviño et al., 2015, p.2). The drugs display anti-cancer 
properties by inducing oxidative damage of the cancer cells. However, the 
chemotherapy regimen has been reported to be ineffective leading to treatment 
failures in 90% of metastatic colon cancer and this has been attributed to 
chemoresistance (Zhao, Butler, & Tan, 2013). The oxidative damage of the cancer 
cells increases the glycolysis of the cells resulting in high levels of the antioxidant 
NADPH, which can be associated with chemoresistance (Wu et al., 2008).  
Colon cancer stems also displays chemoresistance by expressing HIF-1α which 
decreases the pro-apoptotic signaling. The expression of HIF-1α induces the 
expression of decoy receptors like DcR2 which competes for the pro-apoptotic 
signaling factors such as the tumor necrosis factor-related apoptosis inducing ligand. 
This reduces the signaling through the apoptosis-inducing receptors and, therefore, 
attenuates apoptosis thereby allowing cells to tolerate high levels of chemotherapeutic 
agents (Chen et al., 2009; Flamant et al., 2010; Sullivan & Graham, 2009; Wen et al., 
2010). Indeed, there is research evidence to show that most colon cancer stem cells 
are insensitive to chemotherapy and immunotherapy, leading to the development of 
resistance to chemotherapy (Dhawan et al., 2011).  
62 
 
The cancer stem cells are insensitive to chemotherapy hence the need for 
alternative therapy. Research has shown that immunotherapy with antibodies can be 
utilised as an alternative therapy. For instance, studies have shown that colon cancer 
stem cells that are insensitive to 5FU can be made sensitive by the use of 
interleukin-4 blocking antibody (Todaro et al., 2007, 2008). Similarly, it has been 
demonstrated that the use of anti- epiregulin, epidermal growth factor family 
(anti-EREG) antibodies is an effective immunotherapy against colon cancer 
metastasis (Kobayashi et al., 2012). Therefore, there is research evidence to 
demonstrate the effectiveness of immunotherapy against colon cancer stem cells. 
However, immunotherapy is an expensive alternative to chemotherapy due to the high 
cost of producing, storing and transporting the antibodies (Lynch & Murphy, 2016).  
Alternatively, nanotechnology can also be utilised to suppress colon cancer stem 
cells which are resistant to chemotherapy. For instance, siRNA-mediated knockdown 
of the drug efflux protein MDR1 (the protein is overexpressed in colon cancer stem 
cells) has been described as a nanotechnology method of overcoming 
chemoresistance by the colon cancer stem cells (Liu et al., 2009). However, 
nanotechnology is also an expensive therapy which cannot be afforded by most colon 
cancer patients (Kim et al., 2016). Therefore, a more affordable and effective 
alternative is necessary to overcome the chemoresistance of colon cancer stem cells 
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in the treatment of colon cancers.  
The use of medicinal plants has been utilised as an affordable alternative for 
cancer therapy and can also be utilised to overcome the chemoresistance of colon 
cancer stem cells. For instance, a study by Min, Lim, Kim, Kim, and Kim (2015) 
found that the leaves of Sasa quelpaertensis can inhibit colon cancer stem cells and 
influence gene expression related to stem cell development. In another study, Kumar, 
Kumar, Raina, Agarwal and Agarwal (2014) found that grape seed extract can inhibit 
the effect of colon cancer stem cells. P. oleracea extracts, a traditional Chinese 
medicine can prevent and treat colon cancer. Extracts of the plant have been to inhibit 
a number of different cancer cell types (H.-Y. Jin et al., 2012). However, at present no 
study has yet determined the effect of P. oleracea extract on colon cancer stem cells. 
Therefore, this study investigated the effects of P. oleracea extracts on HT-29 stem 
cells and HT-29 cells. 
3.3 Materials and Methods 
3.3.1 P. oleracea Extract Identification and Concentration Determination 
  The compound was extracted according to manufacturer's protocol, which is 
summarized as follows: 50 g of decocted P. oleracea were pulverized for 
approximately three minutes, boiled, and refluxed for 1.5 hours with 10 times the 
volume of 50% ethyl alcohol. P. oleracea was filtered by 200 mesh sieve filtrations 
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and the residue was extracted twice in the manner described above. The filtrates were 
combined three times to reach a final volume of 100 mL and incubated in a heated 
water bath (temperature 95°C). Vacuum distillation was performed to transform the 
concentrated solution into oil, which was dissolved in 50 mL of ultrapure water and 
centrifuged at 12000 x g for 20 min. The supernatant was retained and the sample 
solution was read at 510 nm.  
3.3.2 High-performance liquid chromatography-Mass Spectrometry Analysis of P. 
oleracea Extracts 
High-performance liquid chromatography (HPLC) was used to identify, quantify 
and purify the individual components of the compounds present in the plant extract. 
The P. oleracea extract was dissolved in methanol and water prior to mass 
spectrometry with a method previously described by De Vos, Schipper and Hall 
(2011). The analysis was carried out using Perkin Elmer Turbo Mass 
Spectrophotometer (Norwalk, CTO6859, and USA). The column used was ODS 
column Hedera ODS-2 column measuring 250mm × 4.6 mm at a temperature of 
25OC. The mobile phase was 0.1% (v/v) formic acid in acetic acid acetonitrile. The 
flow rate was 1 ml/min. The UV detector was operated at a wavelength of 358 nm.   
3.3.3 Proliferation Assessment of HT-29 cells and HT-29 Stem Cells 
HT-29 colon cancer stem cells and HT-29 stem cells were seeded in 21 wells of a 
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96-well plate at a concentration of 5×103; 100 μL of medium was added to each well 
that did not contain cells. The P. oleracea ethyl alcohol extract was dissolved in the 
complete medium after adding DMSO (concentration of less than 0.01%). After 24 hr 
and normal cell culture conditions, cells from each of the 21 wells were divided into 
seven treatment groups. Each group was cultured in triplicate and P. 
oleracea-containing medium was added at 200 μL to a final concentration that was 
dependent on the treatment group, as follows: 0 (control group), 0.07 μg/mL, 0.14 
μg/mL, 0.28 μg/mL, 0.56 μg/mL, 1.12 μg/mL, and 2.25 μg/mL (experimental group). 
Cells were then placed in an incubator at 37°C and 5% CO2. After incubation for 24 
or 72 hours, MTT reaction liquid was added to the wells at a ratio of 100 μL:10 μL 
MTT. Following another 1 hour period in the 37°C incubator, the absorbency at 450 
nm (A value) was determined with a microplate reader. The following equation was 
used: inhibition rate = [1 - (A value/drug adding group - A value/blank control 
group)/(A value /drug group - A value /blank control group)]×100%.  
3.3.4 Flow Cytometry Assay for Apoptosis after Treatment of Cells with P. 
oleracea 
HT-29 cells and HT-29 stem cells were scattered and digested with 
EDTA-containing trypsin into single cell suspensions. Cells were stained with trypan 
blue, the number of live cells was counted, and the living cell concentration was 
adjusted to 1 × 104 cells/ ml. Cells were seeded into 6-well plates at 1 × 105 cells/well. 
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After conventional culturing for 24 hours, the cell medium was changed and the 
complete solution with P. oleracea ethyl alcohol was added at 2.25 µg/ml. No drugs 
were added to the control group: only culture medium was present. After 72 hours of 
reaction, the old solution was discarded and the cells were washed once with PBS, 
before adding 1 mL of a digestive solution containing EDTA and trypsin, which was 
incubated for 1-2 min at 37°C. Cells were observed carefully, and at the point when 
they exhibited around appearance serum-containing medium was added to stop the 
digestion. Using a sucker device to blow and suck several times, the cells detached to 
form a monoplast suspension, and were moved to centrifuge tubes and incubated for 
1 hours at 37°C. The cells were centrifuged at 2000 rpm for 5mins at room 
temperature and re-suspended with 500µl of annexin binding buffer. In the dark, 5.0 
µL of Annexin V-FITC(AV) and propidium iodide (PI) dye was added and allowed to 
mix for 15 min at 4°C, followed by analysis by flow cytometry. PI dye excites with 
an argon ion laser: the excitation light wavelength is 488 nm with an emission 
wavelength of over 630 nm (red). The subsequent analysis included blue to red 
fluorescence scatterplots or topographic maps.  
3.3.5 Statistical Analysis  
 All the experimental data were analyzed using SPSS statistical software 
version 13.0 (IBM, Chicago, IL). A confidence interval of 95% was used and, 
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therefore p-values of less than 0.05 were considered statistically significant.  
3.4 Results 
3.4.1 Compounds Present in P. oleracea Extracts, Identified by HPLC-MS 
The mass spectrometry analysis of the ethanol extracts of P. oleracea showed 
that the plant contains five flavonoid components; quercetin, kaempferol, myricetin, 
apigenin, and luteolin (Figure 2.1). The HPLC analysis also identified non-flavonoid 
components of the extract(Figure 2.2); cyclopentanecarboxylic acid, furan, 9H-
Fluorene, benzeneacetic acid, andazaheneicosanoic acid (Table 2.1). 
 
Figure 3.1: Flavonoid Components XIC Manager screening of Ethanol P. 
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oleracea Extracts with water(A) and extract with ethanol(B).  
 
Figure 3.2 HPLC chromatogram of P.oleracea extract with water(A) and 
extract with ethanol(B) The components were identified by mass spectrometry 
analysis at a mobile phase of 0.1% (v/v) formic acid in acetic acid acetonitrile. The 
UV detector was operated at a wavelength of 358 nm and separation performed on an 
ODS column Hedera ODS-2 column (250mm × 4.6mm) at a temperature of 25OC.  
69 
 
 
 
 
Table 3.1 
Non-flavonoid Components of Ethanol Extracts of P. oleracea  
Peak 
NO 
Molecular 
formula Identification 
Structure 
1 C35H44O6 
Cyclopentanecarboxylic 
acid, 1-[2-[2-[2-
(triphenylmethoxy) ethoxy]
ethoxy]ethoxy]-, 1,1-
dimethylethyl ester 
 
2 C32H36O2 
Furan, 4-(1,1-
dimethylethyl)-5-[4-(9,9-
dimethyl-9H-fluoren-2-yl)-3-
methoxyphenyl]-2,3-
dihydro-3,3-dimethyl- 
 
3 C39H40O4 
9H-Fluorene, 9-[2,4-
cyclopentadien-1-ylbis(3,4-
dimethoxyphenyl)methyl]-2,
3,6,7-tetramethyl- 
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4 C35H40O6 
Benzeneacetic acid, 3,5-
bis(phenylmethoxy)-, (1R,
2S,5E)-1,2,6-trimethyl-7-
oxo-7-(2-propen-1-yloxy)-5-
hepten-1-yl ester, rel- 
 
5 C36H36O 
9H-Fluorene, 9-[2-[3-[1-
ethyl-1-(2-methoxyphenyl)
propyl]-1H-inden-1-yl]ethyl]
- 
 
6 C18H35NO9 
5,8,11,14,17,20-Hexaoxa-
3-azaheneicosanoic acid, 2-
(2-methylpropyl)-4-oxo-, 
(2S)- 
 
 
3.4.2 Effect of P. oleracea extracts on the Proliferation of HT-29 Cells and HT-29 
Stem Cells 
The results of a proliferation assay showed that HT-29 cells proliferated more 
slowly than HT-29 stem cells (Figure 2.2). P. oleracea extracts exerted an inhibitory 
effect on the proliferation of HT-29 cells and HT-29 stem cells after 72 hours at 
concentrations ranging from 0.07 - 2.25 μg/mL, and the level of inhibition was found 
to increase with dosage (Figure 2.2). Interestingly, P. oleracea extracts had a 
significantly more potent effect on HT-29 colon cancer cells than on HT-29 colon 
cancer stem cells, based on a repeated measurement data comparisons analysis of 
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different treatment concentrations (p < 0.001). However, for both cell types, as the 
concentration increased, the difference in the rate of proliferation inhibition was 
reduced. 
 
 
 
 
Figure 3.3: Proliferation Assay for HT-29 Cells and HT-29 Stem Cells and the 
Effect of P. oleracea Extract. Stem cells were treated with varying concentrations of 
P. oleracea extract, as indicated, and the effect on proliferation of both cell types was 
measured after 72 hours of culture. The inhibition rate was determined by an MTT 
assay, and the ratio was calculated as indicated in the methods. An increased 
inhibition ratio is associated with a significantly higher inhibition rate of proliferation 
(p-value < 0.001).  
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3.4.3 The effect of P. oleracea Extracts on Apoptosis, as Measured by Flow 
Cytometry. 
Treatment with P. oleracea extract (2.25 µg/mL) resulted in a significant increase 
in apoptosis in both HT-29 stem cells and HT-29 cells (Figure 2.3; p <0.05 and 
p<0.025, respectively) compared to untreated controls. Taken together with the 
previous section, this result suggests that P. oleracea extract can inhibit the 
proliferation of cancer stem cells by inducing apoptosis.  
 
Figure 3.4: The Effects of P. oleracea Extracts on Apoptosis of HT-29 Cells and 
HT-29 Stem Cells. Cells were stained for markers of cell viability: propidium iodine 
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(PI) and Annexin V (AV). Viable cells are AV and PI negative. Increased uptake of 
AV is correlated with apoptosis. Double staining with AV and PI is consistent with 
late apoptosis or dead cells. (A) Untreated HT-29 cells (B) HT-29 cells treated with 
2.25 µg/mL P. oleracea (C) Untreated HT-29 stem cells (D) HT-29 stem cells treated 
with 2.25 µg/mL P. oleracea. (E) Quantification of flow cytometry data shown in 
A-D. AV positive cells were considered apoptotic (upper and lower right quadrants).  
3.5 Discussion  
The results of this study showed that P. oleracea extracts can inhibit the 
proliferation of both colon cancer cells and colon cancer stem cells in a 
dose-dependent manner. When treated with lower concentrations of P. oleracea, the 
inhibition rate was higher in colon cancer cells than in colon cancer stem cells by 
more than a two-fold difference. Additionally, P. oleracea extracts induced apoptosis 
in both cell types. The dosage used in this study was a comparatively low dose of P. 
oleracea extract. A study by Al-Sheddi et al. (2015) utilized doses of 250-1000 
µg/mL to inhibit the liver cancer cell line HepG2 and lung cancer cell line A-549, the 
lowest dose being 100 times higher than the highest dose in this study.  
Similarly, many previous studies have found beneficial effects of P. oleracea on 
cancer cells. For instance, a study by Ji et al. (2015) showed that P. oleracea extract 
inhibits the proliferation, invasion, and metastasis of the liver cancer cell line 
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HCCLM3. Another study by Gu et al. (2015) found that both fresh and dry P. 
oleracea extract inhibit liver cancer cell proliferation and have anti-oxidant effects. In 
addition, Farshori et al. (2014) reported that P. oleracea extract can inhibit the 
influence of liver cancer cells. Finally, a study by Zhao et al. (2013) found that P. 
oleracea extracts can inhibit cervical cancer cells. However, this is the first study to 
show that P. oleracea has a similar influence on colon cancer and can inhibit colon 
cancer stem cells.  
3.6 Conclusion  
 In conclusion, the results of this study show that P. oleracea extracts can inhibit 
the proliferation and increases the apoptosis of colon cancer stem cells at the cellular 
level in a dose-dependent manner. These results provide a new basis for the 
prevention and treatment of colon cancer at the level of colon cancer stem cells using 
P. oleracea extracts.  
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4.0 Chapter 3: The Effects of P. oleracea Extracts on the Expression of Notch1, 
Notch2, and Beta-Catenin mRNA in HT-29 Cells and HT-29 Stem Cells 
4.1 Abstract 
The Notch signal transduction pathway has been shown to be important for the 
development of colon cancer stem cells (H.-Y. Jin et al., 2012; Qiao & Wong, 2009). 
After translation, the Notch pathway has also been shown to regulate the 
Beta-Catenin mRNA in stem cells (Kwon et al., 2011). This study investigated the 
effect of P. oleracea extracts on the expression of Notch1, Notch2, and Beta-Catenin 
mRNA in HT-29 cells and HT-29 stem cells. It was found that P. oleracea extracts 
significantly down-regulate the expression of Notch1 and β-catenin in both HT-29 
cells and HT-29 stem cells. However, the treatment of HT-29 cells and HT-29 stem 
cells with P. oleracea extract caused a slight increase in expression of Notch2, 
although this difference was not statistically significant. This suggests that alterations 
in the Notch signal transduction pathway underlie the inhibitory effects of P. oleracea 
on proliferation, as well as the increase in apoptosis, of colon cancer stem cells.4 
                                                        
4 The material contained in this chapter was already submitted to Tumor Biology. 
83 
 
 
4.2 Introduction 
The main properties of colon cancer stem cells (which plays a significant role in 
the development, recurrence, and metastasis of colon cancers) include self-renewal 
potential, ability to differentiate into diverse cell populations and ability to balance 
and modulate the processes of self-renewal and differentiation (Garza-Treviño et al., 
2015). Self-renewal refers to the ability of the colon cancer stem cells synthesize new 
cells with the same ability to proliferate, expand and differentiate as the parental cells 
thereby maintaining a pool of the stem cell (Garza-Treviño et al., 2015). The 
mechanisms utilised for the self-renewal of the colon cancer stem cells, such as the 
Wnt/β-catenin and Notch pathways, makes use of proto-oncogenes. In addition, the 
self-renewal pathway of colon cancer stem cells is regulated by the sonic hedgehog 
(Hh) signaling pathway, a pathway commonly reported in multiple myeloma (Varnat 
et al., 2009). Research has shown that the self-renewal of colon cancer stem cells is 
promoted by the Wnt pathway and the prevention of the β-catenin-dependent 
transcription (Ong et al., 2014). 
Additionally, the Notch receptors pathway has also been reported to promote the 
self-renewal of colon cancer stem cells (Ong et al., 2014). In the Notch pathway, the 
DLL4 genes stimulate the Notch receptors on adjacent cells and in combination with 
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the effects of β-catenin promotes the self-renewal of the cancer stem cells by 
directing an immature transcription profile (Garza-Treviño et al., 2015). However, the 
self-renewal pathways are inhibited by BMP4 genes which bind BMP receptors 
leading to interference with the Wnt pathway and thus promote cell differentiation. 
The process of differentiation has also been reported to be inhibited by hepatocyte 
growth factor (HGF) leading to the maintenance of the cells in a stem-cell state (Ong 
et al., 2014).   
Cancer stem cells also have the ability into differentiate into diverse cell 
populations (Garza-Treviño et al., 2015). That is, the stem cells have the ability to 
differentiate into a heterogeneous progeny of cells that can undergo progressive 
diversification and specialization following self-renewal. The cells of this 
differentiation are specialized to carry out certain unique physiological functions 
(Dalerba, Cho, et al., 2007). However, histopathological studies of colon cancers have 
indicated that the cells are relatively undifferentiated containing higher proportions of 
colon cancer stem cells than more differentiated cancer cells (Ashley et al., 2013; 
Merlos-Suárez et al., 2011). The undifferentiated colon cancer cells have worse 
clinical prognosis compared to differentiated cancer cells (Merlos-Suárez et al., 
2011).  
Homeostatic control where the cells have the ability to balance and modulate the 
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processes of self-renewal and differentiation is also a key property of cancer stem 
cells (Garza-Treviño et al., 2015). Through research, it has been established that 
differentiated intestinal epithelial cells reside in the intestinal crypts as repeats of 
stem cells containing leucine and B lymphoma Mo-MLV insertion region 1 homolog 
(Bmi-1) or G protein-coupled receptor 5 (Lgr5) (Tian et al., 2011). The Bmi-1 AND 
Lgr5 are used to maintain the capacity of tissues to regenerate (Tian et al., 2011). The 
intestinal cells that express Lgr5 undergo active proliferation and very sensitive to 
stimulatory effects of Wnt and Dkk1-mediated Wnt inhibition (Tian et al., 2011). On 
the other hand, intestinal cells that express Bmi-1 are less sensitive to environmental 
stressors and are, therefore, not affected by the Wnt modulation. The 
Bmi-1-expressing intestinal cells are normally quiescent, only giving rise to cell 
progeny under certain conditions (Yan et al., 2012). The Wnt proteins and the Notch 
pathway has been reported to play a significant role in maintaining cancer stem cells 
hemostasis by providing signals required for the maintenance of the phenotype of 
colon cancer stem cells in the tumour mass (Garza-Treviño et al., 2015).  
Based on these three properties of colon cancer stem cells, it can be deduced that 
the dysregulation of the Notch pathway and Beta-Catenin mRNA plays a role in the 
development of cancer. Therefore, the ability of P. oleracea extracts to inhibit the 
proliferation but promote the apoptosis of colon cancer stem cells, in case of any, 
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may suggest that the extracts dysregulate the Notch pathway and Beta-Catenin 
mRNA. However, there is no study that has investigated the effect of P. oleracea 
extracts on the expression of Notch1, Notch2, and Beta-Catenin mRNA in HT-29 
cells and HT-29 stem cells. Therefore, this study investigated the effect of P. 
oleracea extracts on the expression of Notch1, Notch2, and Beta-Catenin mRNA in 
HT-29 cells and HT-29 stem cells.   
4.3 Materials and Methods 
4.3.1 Real-time Fluorescence Quantitative PCR (FQ-PCR) Assay for the 
Expression of Notch1, Notch2, and β-catenin mRNA   
HT29 cells were cultured in McCoy's 5A medium with 10% FBS, while HT29 
stem cells were cultured in RPMI-1640 medium with 10% FBS. Both cell strains 
were seeded at a concentration of 5 × 105 cells/mL in complete medium containing 10 
cm dishes, with two dishes for each strain. After 24 hours under normal conditions, a 
complete medium that contained the following concentrations of P. oleracea extract 
was added: 0 μg/mL (control group) or 2.25 μg/mL (experiment group). After 72 
hours in an incubator at 37° and 5% C02, the cells were washed twice with pre-cooled 
PBS. Total RNA was isolated with Trizol kit. RNA was reverse-transcribed to cDNA 
(Real Time PCR) using the primers shown in Table 3.1. Ribosome 18S (18S rRNA) 
was used as an internal reference.  
Table 4.1 
Primers used for the Quantitative RT-PCR Assay 
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Gene Primer Primer sequence Length 
Notch1 Notch1 (+) CCGCAGCACTATTGAGAACA 213 bp 
Notch1 (-) ATCCATGTGTAGCCGTAGCC 
Notch2 Notch2 (+) TAATACGACTCACTATGAGA 229 bp 
Notch2 (-) ATTTAGGTGACACTATCTGT 
β-catenin β-catenin (+) AAGTTCTTGGCTATTACGCA 203 bp 
β-catenin (-) ACAGCACCTTCAGCACTATG 
18s rRNA 18s rRNA (+) TTTGTTGGTTTTCGGAACTGA 198 bp 
18s rRNA (–) CGTTTATGGTCGGAACTACGA 
 
4.3.2 Western Blot Assays for the Expression of ß-catenin, Notch1, and Notch2 
Proteins 
HT-29 cells and HT-29 stem cells were treated with 2.25 μg/mL of P. oleracea 
extract, a cell scraper was used to lift cells in the primary culture solution, total 
protein was extracted, and a Western blot assay was prepared, according to the 
manufacturer. The total grey value in the resulting Western blots was measured with 
Band Scan Analysis software, which allowed for a quantitative comparative analysis. 
Measurements were normalized to β-actin. 
4.3.3 Statistical Analysis  
 All the experimental data were analyzed using SPSS statistical software version 
13.0 (IBM, Chicago, IL). A confidence interval of 95% was used and, therefore 
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p-values of less than 0.05 were considered statistically significant. 
4.4 Results 
4.4.1 Expression of Notch1, Notch2, And Β-Catenin mRNA in HT-29 Colon 
Cancer Cells And HT-29 Colon Cancer Stem Cells with and Without 
Treatment with P. Oleracea Extracts.   
At baseline, the expression of Notch1, Notch2, and β-catenin mRNA was lower 
in HT-29 colon cancer cell lines than in HT-29 colon cancer stem cells. While the 
differences in the expression of Notch1 and β-catenin were statistically significant, 
the differences in Notch2 were not significant (Table 3.2). After treatment with P. 
oleracea extract (2.25 μg/mL), the expression of Notch1 and β-catenin in both HT-29 
cells and HT-29 stem cells were significantly down-regulated. Conversely, treatment 
with P. oleracea extract caused a slight increase in expression of Notch2, although 
this difference was not statistically significant (Table 3.3). 
 
 
 
 
Table 4.2 
Expression of Notch1, Notch2, and β-catenin mRNA in HT-29 cells and HT-29 
stem cells 
 HT-29 cells (mean±SD) 
HT-29 stem 
cells(mean±SD) p-value 
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Table 4.3 
Expression of Notch1, Notch2, and β-catenin mRNA in HT-29 cells and 
HT-29 stem cells after treatment with P. oleracea (mean±SD) 
 
 β-catenin Notch1 Notch2 
    HT-29 cells 1.16 ± 0.17 1.01 ± 0.01 1.11 ± 0.11 
+ P. oleracea 0.003 ± 0.0004 0.004 ± 0.001 1.93 ± 0.30 
p-value 0.000 0.000 0.32 
HT-29 stem cells 2.34 ± 0.28 1.66 ± 0.03 1.16 ± 0.10 
+ P. oleracea 0.003 ± 0.001 0.003 ± 0.0003 1.37 ± 0.067 
p-value <0.001 <0.001 0.053 
 
4.4.2 Results of Western Blot Analyses for β-catenin, Notch1, and Notch2 
Treatment with P. oleracea extracts decreased the expression of Notch1, Notch2, 
and β-catenin protein in HT-29 cells and HT-29 stem cells (Table 3.4, Figure 3.1). 
 
 
 
 
 
β-catenin 1.16 ± 0.17 2.34 ± 0.28 0.003 
Notch1 1.01 ± 0.01 1.66 ± 0.03 <0.001 
Notch2 1.11 ± 0.11 1.16 ± 0.10 0.584 
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Table 4.4 
Relative expression of Notch1, Notch2, and β-catenin proteins in HT-29 cells 
and HT-29 stem cells after treatment with P. oleracea compared to β-actin 
 β-catenin Notch1 Notch2 
HT-29 stem cells 1.64  1.26 0.69 
HT-29 stem cells + P. oleracea 0.16 0.41 0.03 
p-value 0.027 0.032 0.052 
HT-29 cells 0.70 0.45 0.17 
HT-29 cells + P. oleracea 0.55 0.32 0.05 
p-value 0.002 0.011 0.355 
   
 
Figure 4.1: Representative Western blots for the expression of proteins in the 
Notch signal transduction pathway after treatment with P. oleracea. Lane 1: 
HT-29 stem cells + P. oleracea; Lane 2: HT-29 cells + P. oleracea; Lane 3: HT-29 
stem cells; Lane 4: HT-29 cells.  
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4.5 Discussion 
The Notch signal transduction pathway is an important regulator gene for the 
development of colon cancer stem cells (H.-Y. Jin et al., 2012; Qiao & Wong, 2009). 
Preliminary results have shown that tea polyphenol can inhibit and regulate the 
genetic effects of the Notch signal transduction pathway (H. Jin, Tan, Liu, & Ding, 
2010). The target genes of the Notch signal transduction pathway are closely related 
to colon cancer stem cells and include Notch1, Notch2, and β-catenin. In this study, it 
was found that the expression of Notch1 and β-catenin mRNA was significantly 
higher in colon cancer stem cells than in colon cancer cell lines. This suggests that 
Notch1 and β-catenin gene expression decreases when colon cancer stem cells mature. 
However, the reason for this is unclear and requires further study. Importantly, this 
study established that treatment with P. oleracea extracts inhibited the expression of 
Notch1 and β-catenin mRNA by close to 10-fold. Taken together, it is possible that 
alterations in the Notch signal transduction pathway underlie the inhibitory effects of 
P. oleracea on proliferation, as well as the increase in apoptosis, of colon cancer stem 
cells. At present, there are only a limited number of studies on P. oleracea extract; 
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therefore, next study will continue to explore the possible mechanisms underlying 
these suppressive effects on colon cancer stem cells. 
4.6 Conclusion 
In conclusion, this study established that P. oleracea extracts significantly inhibit 
the expression of Notch1 and β-catenin mRNA by close to 10-fold, suggesting that 
alterations in the Notch signal transduction pathway underlie the inhibitory effects of 
P. oleracea on proliferation, as well as the increase in apoptosis, of colon cancer stem 
cells.  
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5.0 Summary and Future Perspective  
Given the importance of preventing and treating colon cancer at the level of the 
cell, a number of difference avenues have been explored for inhibiting colon cancer 
stem cells. Aside from immunological therapy, chemotherapy, and the other standard 
treatments, some investigators have reported on the merits of using natural drugs or 
foods to prevent and treat this disease. For example, a study by Min, Lim, Kim, Kim, 
and Kim (2015) found that the leaves of Sasa quelpaertensis can inhibit colon cancer 
stem cells and influence gene expression related to stem cell development. In another 
study, Kumar, Kumar, Raina, Agarwal and Agarwal (2014) found that grape seed 
extract can inhibit the effect of colon cancer stem cells. Similarly, in this study, 
alcohol was used to extract the flavone content of P. oleracea, and this extract was 
found to inhibit colon cancer and colon cancer stem cells. These findings suggest that 
P. oleracea extract could represent a potential option in the prevention and treatment 
of colon cancer, as well as for adjuvant therapy. 
The results of this study demonstrated that P. oleracea extracts can inhibit colon 
cancer stem cells at the cellular level in a dose-dependent manner. This result 
provides a new basis for the prevention and treatment of colon cancer at the level of 
colon cancer stem cells using P. oleracea extracts. This study also established that P. 
oleracea extracts significantly inhibit the expression of Notch1 and β-catenin mRNA 
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by close to 10-fold, suggesting that alterations in the Notch signal transduction 
pathway underlie the inhibitory effects of P. oleracea on proliferation, as well as the 
increase in apoptosis, of colon cancer stem cells. However, further studies should be 
conducted to explore the possible mechanisms underlying these suppressive effects 
on colon cancer stem cells considering the limited number of studies on P. oleracea 
extracts in this area currently.  
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